Cargando…

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine

The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dong, An, Chaoqiang, Bai, Yu, Li, Kelei, Liu, Jianyang, Wang, Qian, He, Qian, Song, Ziyang, Zhang, Jialu, Song, Lifang, Cui, Bopei, Mao, Qunying, Jiang, Wei, Liang, Zhenglun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504790/ https://www.ncbi.nlm.nih.gov/pubmed/36146661 http://dx.doi.org/10.3390/v14091854

Ejemplares similares

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I
por: Song, Ziyang, et al.
Publicado: (2022)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

Construction and verification of an infectious cDNA clone of coxsackievirus B5
por: Song, Lifang, et al.
Publicado: (2022)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
por: Cui, Bopei, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine
por: Gao, Fan, et al.
Publicado: (2022)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

Research progress on circular RNA vaccines
por: Bai, Yu, et al.
Publicado: (2023)

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content
por: Han, Lu, et al.
Publicado: (2022)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
por: Bian, Lianlian, et al.
Publicado: (2021)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept
por: Liu, Jianyang, et al.
Publicado: (2023)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5
por: Mao, Qunying, et al.
Publicado: (2018)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
por: Liu, Pei, et al.
Publicado: (2021)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains
por: Huo, Yaqian, et al.
Publicado: (2021)

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice
por: Mao, Qunying, et al.
Publicado: (2012)

Recombination in Positive-Strand RNA Viruses
por: Wang, Haiwei, et al.
Publicado: (2022)

Evaluation of Thimerosal Removal on Immunogenicity of Aluminum Salts Adjuvanted Recombinant Hepatitis B Vaccine
por: Mahboubi, Arash, et al.
Publicado: (2012)

Research Advances on the Stability of mRNA Vaccines
por: Cheng, Feiran, et al.
Publicado: (2023)

Recombinant chicken interleukin-7 as a potent adjuvant increases the immunogenicity and protection of inactivated infectious bursal disease vaccine
por: Cui, Dan, et al.
Publicado: (2018)

Influence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles
por: Brzuska, Gabriela, et al.
Publicado: (2022)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial
por: Li, Yan, et al.
Publicado: (2021)

A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy
por: Song, Ying-Chyi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ogb2cuvfrps4k9bnd5vpan6lss